| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA821: Avalglucosidase alfa for treating Pompe disease |
|
Medicine details |
|
| Medicine name | avalglucosidase alfa (Nexviadyme®) |
| Formulation | intravenous injection |
| Reference number | 3239 |
| Indication | Long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid α-glucosidase deficiency) |
| Company | Genzyme Therapeutics |
| BNF chapter | Nutrition & blood |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 10/12/2021 |
| NICE guidance | |